Inactive Instrument

Analyst Reco. Aptose Biosciences Nasdaq

Equities

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	11-10	MT
Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	11/08/23	MT
HC Wainwright & Co. Adjusts Price Target on Aptose Biosciences to $23 From $12, Maintains Buy Rating	11/08/23	MT
RBC Cuts Price Target on Aptose Biosciences to $23 From $40, Keeps Outperform Rating, Speculative Risk Qualifier	11/08/23	MT
Piper Sandler Initiates Aptose Biosciences at Overweight Rating With $37 Price Target	12/06/23	MT
Oppenheimer Adjusts Aptose Biosciences Price Target to $50 From $9, Maintains Outperform Rating	12/06/23	MT
Piper Sandler Adjusts Aptose Biosciences' Price Target to $37 From $45, Keeps Overweight Rating	07/06/23	MT
RBC Adjusts Price Target on Aptose Biosciences to $40 From $75 Amid Reverse Stock Split, Keeps Outperform, Speculative Risk	07/06/23	MT
RBC Capital Maintains Outperform/Speculative Rating, US$5 Target on Aptose Biosciences After Q1	09/05/23	MT
Canaccord Genuity Adjusts Aptose Biosciences Price Target to $8 From $13, Maintains Buy Rating	27/03/23	MT
RBC Trims Aptose Biosciences' Price Target to $5 From $6, Keeps Outperform Rating, Speculative Risk Qualifier	02/11/22	MT
RBC Capital Maintains Outperform/Speculative Risk Rating, US$6 TP on Aptose Biosciences After CFO Appointment	28/06/22	MT
RBC Cuts Price Target on Aptose Biosciences to $6 From $7, Maintains Outperform Rating, Speculative Risk Qualifier	10/05/22	MT
RBC Capital Keeps Outperform/Speculative Risk, US$7 TP on Aptose Biosciences After Q4 Results	23/03/22	MT
RBC Capital Keeps Outperform/Speculative Risk Rating, US$7 TP on Aptose Biosciences	11/01/22	MT
RBC Cuts Price Target on Aptose Biosciences to $7 From $9, Maintains Outperform Rating, Speculative Risk Qualifier	06/01/22	MT
HC Wainwright Adjusts Aptose Biosciences' Price Target to $12 From $14, Keeps Buy Rating	21/12/21	MT
RBC Capital Reiterates Outperform/Speculative Risk Rating, US$9 TP on Aptose Biosciences	14/12/21	MT
RBC Capital Markets Keeps Rating on Aptose Biosciences Unchanged After "Uneventful" Q3 Earnings Call	12/11/21	MT
HC Wainwright Adjusts Aptose Biosciences' Price Target to $14 From $9, Reiterates Buy Rating	12/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aptose Biosciences Nasdaq

Equities

Analyst Reco.

Filters